Aggressive behavior in patients with intellectual disability can be resistant to pharmacological treatment and have detrimental consequences to themselves, family members, and caregivers. Hypothalamic deep brain stimulation (DBS) has been used to improve this type of behavior in severe and refractory cases. Here, we present the description and analysis of DBS of the posteromedial hypothalamus (PMH) and its long-term impact as treatment to improve severe and refractory aggressive behaviors, even with previous bilateral hypothalamotomy without improvement in patients with intellectual disability. Eleven patients underwent bilateral DBS of the PMH. Their medical records were reviewed, and the impact on behavior was measured using preoperative and postoperative Modified Overt Aggression Scale (MOAS) during the last follow-up medical visit. Nine of 11 patients presented a significant decrease in the severity of aggressive behavior, with a preoperative and postoperative MOAS average value of 50.5 and 18.7, respectively. An overall improvement of 63% was seen with a mean follow-up time of 4 years. A patient who previously underwent a bilateral hypothalamotomy via radiofrequency was included in this group. During follow-up, 3 patients presented deterioration of symptoms subsequent to pulse generator depletion but made a full clinical recovery after battery replacement. We posit that DBS of the PMH may be a safe and effective in improving severe and refractory aggressive behavior in patients with long-term intellectual disability.

1.
Siegel
A
,
Victoroff
J
.
Understanding human aggression: new insights from neuroscience
.
Int J Law Psychiatry
.
2009
;
32
(
4
):
209
15
. .
2.
Sano
K
,
Mayanagi
Y
,
Sekino
H
,
Ogashiwa
M
,
Ishijima
B
.
Results of stimulation and destruction of the posterior hypothalamus in man
.
J Neurosurg
.
1970
;
33
(
6
):
689
707
. .
3.
Tarnecki
R
,
Mempel
E
,
Fonberg
E
,
Lagowska
J
.
Some electrophysiological characteristics of the spontaneous activity of the amygdala and effect of hypothalamic stimulation on the amygdalar units responses
.
Acta Neurochir
.
1976
;
23
(
Suppl l
):
135
40
. .
4.
Choi
SH
,
Kim
YB
,
Paek
SH
,
Cho
ZH
.
Papez circuit observed by in vivo human brain with 7.0T MRI super-resolution track density imaging and track tracing
.
Front Neuroanat
.
2019
;
13
:
17
. .
5.
Gouveia
FV
,
Hamani
C
,
Fonoff
ET
,
Brentani
H
,
Alho
EJL
,
de Morais
RMCB
,
Amygdala and hypothalamus: historical overview with focus on aggression
.
Neurosurgery
.
2019
;
85
(
1
):
nyy635
.
6.
Franzini
A
,
Broggi
G
,
Cordella
R
,
Dones
I
,
Messina
G
.
Deep-brain stimulation for aggressive and disruptive behavior
.
World Neurosurg
.
2013
;
80
(
3–4
):
S29
4
. .
7.
Benedetti‐Isaac
JC
,
Torres‐Zambrano
M
,
Vargas‐Toscano
A
,
Perea‐Castro
E
,
Alcalá‐Cerra
G
,
Furlanetti
LL
,
Seizure frequency reduction after posteromedial hypothalamus deep brain stimulation in drug‐resistant epilepsy associated with intractable aggressive behavior
.
Epilepsia
.
2015
;
56
(
7
):
1152
61
.
8.
Torres
CV
,
Sola
RG
,
Pastor
J
,
Pedrosa
M
,
Navas
M
,
García-Navarrete
E
,
Long-term results of posteromedial hypothalamic deep brain stimulation for patients with resistant aggressiveness
.
J Neurosurg
.
2013
;
119
(
2
):
277
87
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.